Abstract
Increased aerobic glycolysis in cancer, a phenomenon known as the Warburg effect, has been observed in various tumor cells and represents a major biochemical alteration associated with malignant transformation. Although the exact molecular mechanisms underlying this metabolic change remain to be elucidated, the profound biochemical alteration in cancer cell energy metabolism provides exciting opportunities for the development of therapeutic strategies to preferentially kill cancer cells by targeting the glycolytic pathway. Several small molecules capable of inhibiting glycolysis in experimental systems have been shown to have promising anticancer activity in vitro and in vivo. This review article provides a brief summary of our current understanding of the Warburg effect, the underlying mechanisms, and its influence on the development of therapeutic strategies for cancer treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Albayrak T, Scherhammer V, Schoenfeld N, Braziulis E, Mund T, Bauer MK, Scheffler IE, Grimm S (2003) Mol Biol Cell 14:3082–3096
Altenberg B, Greulich KO (2004) Genomics 84:1014–1020
Arora KK, Pedersen PL (1988) J Biol Chem 263:17422–17428, Nov 25
Barnard JP, Reynafarje B, Pedersen PL (1993) J Biol Chem 268:3654–3661
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) Cell 126:107–120
Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L (2002) J Clin Oncol 20:4150–4159
Biaglow JE, Cerniglia G, Tuttle S, Bakanauskas V, Stevens C, McKenna G (1997) Biochem Biophys Res Commun 235:739–742
Brand KA, Hermfisse U (1997) FASEB J 11:388–395
Brandon M, Baldi P, Wallace DC (2006) Oncogene 25:4647–4662
Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schoffski P, Raoul JL, Hess D, Selvais R, Lacombe D, Bachmann P, Fumoleau P (2003) Eur J Cancer 39:2334–2340
Burgering BM, Coffer PJ (1995) Nature 376:599–602
Carew JS, Huang P (2002) Molecular Cancer 1:1–12
Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P (2003) Leukemia 17:1437–1447
Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P (2004) Leukemia 18:1934–1940
Chesney J (2006) Curr Opin Clin Nutr Metab Care 9:535–539
Coy JF, Dressler D, Wilde J, Schubert P (2005) Clin Lab 51:257–273
Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Cognetti F (2003) Drugs Today (Barc) 39:157–174
Fantin VR, St-Pierre J, Leder P (2006) Cancer Cell 9:425–434
Flier JS, Mueckler MM, Usher P, Lodish HF (1987) Science 235:1492–1495
Floridi A, Bruno T, Miccadei S, Fanciulli M, Federico A, Paggi MG (1998) Biochem Pharmacol 56:841–849
Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C (1981) J Natl Cancer Inst 66:497–499
Giaccone G, Smit EF, de Jonge M, Dansin E, Briasoulis E, Ardizzoni A, Douillard JY, Spaeth D, Lacombe D, Baron B, Bachmann P, Fumoleau P (2004) Eur J Cancer 40:667–672
Gatenby RA, Gillies RJ (2004) Nat Rev Cancer 4:891–899
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Cancer Res 62:3909–3913
Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2004) Cancer Res 64:31–34
Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ (2004) Clin Cancer Res 10:6661–6668
Gottlieb E, Tomlinson IP (2005) Nat Rev Cancer 5:857–866
Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N (2001) Genes Dev 15:2203–2208
Harris AL (2001) Nat Rev Cancer 2(1):38–47
Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, Ishii N (2005) Cancer Res 65:203–209
Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) Cell Metab 3:177–185
Ko YH, Pedersen PL, Geschwind JF (2001) Cancer Lett 173:83–91
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Biochem Biophys Res Commun 324:269–275
Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W (2006) Cancer Chemother Pharmacol 58:725–734
Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, Stassi G, Schubert P, Coy JF (2006) Br J Cancer 94:578–585
Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ (2001) Biochemistry 40:5542–5547
Liu H, Savaraj N, Priebe W, Lampidis TJ (2002) Biochem Pharmacol 64:1745–1751
Maher JC, Krishan A, Lampidis TJ (2004) Cancer Chemother Pharmacol 53:116–122
Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Macias-Silva M, Sosa-Garrocho M, Moreno-Sanchez R (2006) FEBS J 273:1975–1988
Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ (2004) Cancer Res 64:31–34
Mathupala SP, Rempel A, Pedersen PL (1995) J Biol Chem 270:16918–16925
Mathupala SP, Ko YH, Pedersen PL (2006) Oncogene 25:4777–4786
Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM (2006) Science 312:1650–1653
Nakashima RA, Paggi MG, Pedersen PL (1984) Cancer Res 44:5702–5706
Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Biochim Biophys Acta 1555:14–20
Pelicano H, Xu R-H, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P (2006a) J Cell Biol 175:913–923
Pelicano H, Martin DS, Xu RH, Huang P (2006b) Oncogene 25:4633–4646
Rais B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany R, Lee WN, Boros LG, Cascante M (1999) FEBS Lett 456:113–118
Ramanathan A, Wang C, Schreiber SL (2005) Proc Natl Acad Sci USA 102:5992–5997
Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB (2003) Mol Cell Biol 23:7315–7328
Robey RB, Hay N (2006) Oncogene 25:4683–4696
Rodriguez-Enriquez S, Torres-Marquez ME, Moreno-Sanchez R (2000) Arch Biochem Biophys 375:21–30
Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E III (1989) Cancer Chemother Pharmacol 25:32–36
Sebastian S, White JA, Wilson JE (1999) J Biol Chem 274:31700–31706
Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E (2005) Cancer Cell 7:77–85
Serkova N, Boros LG (2005) Am J Pharmacogenomics 5:293–302
Shinohara Y, Ichihara J, Terada H (1991) FEBS Lett 291:55–57
Singh K.K. (2004). Ann N Y Acad Sci. 1019, 260–264
Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V (2005) Strahlenther Onkol 181:507–514
Sirover MA (2005) J Cell Biochem 95:45–52
Tian M, Zhang H, Higuchi T, Oriuchi N, Nakasone Y, Takata K, Nakajima N, Mogi K, Endo K (2005) Ann Nucl Med 19:335–338
Warburg O (1956) Science 123:309–314
Warburg O, Negelein E (1924) Biochemische Zeitschrift 152:319–344
Wilson JE (2003) J Exp Biol 206:2049–2057
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P (2005a) Cancer Res 65:613–621
Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P (2005b) Leukemia 19:2153–2158
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, Z., Lu, W., Garcia-Prieto, C. et al. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39, 267–274 (2007). https://doi.org/10.1007/s10863-007-9086-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-007-9086-x